Table 2.
Effusion characteristics (N = 108).
| N | (%) | |
|---|---|---|
| Sample type | ||
| Pleural effusion | 103 | 95.4 |
| Ascites | 5 | 4.6 |
| Cellularity | ||
| Scant | 33 | 30.6 |
| Moderate | 45 | 41.7 |
| Abundant | 30 | 27.8 |
| Cytology | ||
| Negative for malignant cells | 35 | 32.4 |
| Carcinoma or atypical cells | 73 | 67.6 |
| Carcinoma or atypical cell percentage | ||
| 0% | 35 | 32.4 |
| <5% | 41 | 38.0 |
| 5 – 49% | 17 | 15.7 |
| ≥50% | 15 | 13.9 |
| Pellet DNA concentration (ng/μL) | ||
| Mean | 353.0 | |
| Range | 13.3 – 1724.0 | |
| EGFR–TKI exposure history | ||
| EGFR–TKI naïve | 12 | 11.1 |
| First generation EGFR–TKI | 52 | 48.1 |
| Second generation EGFR–TKI | 34 | 31.5 |
| Third generation EGFR–TKI | 1 | 0.9 |
| First and second generation EGFR–TKI | 2 | 1.9 |
| First/second and third generation EGFR–TKI | 7 | 6.5 |
| Last treatment before sampling | ||
| Treatment naïve | 9 | 8.3 |
| First/second generation EGFR–TKI | 49 | 45.4 |
| Third generation EGFR–TKI | 8 | 7.4 |
| Chemotherapy | 39 | 36.1 |
| Treatment-free > 3 months | 3 | 2.8 |
EGFR–TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.